Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

Ulcerative colitis during pregnancy is manageable However timely detection and proper treatment are crucial to ensure a ...

Company on track to report topline data in first half of 2025Positive preliminary data from all five single ascending dose (SAD) cohorts ranging ...

(RTTNews) - Palisade Bio, Inc. (PALI), Thursday announced a preliminary data from five planned Single Ascending Dose cohorts, showing that PALI-2018 was well-tolerated among doses ranging from 15 mg ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

The Phase III trial successfully saw patients achieving clinical remission and stopping rectal bleeding within 28 days.

CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company with a market capitalization of ...

CU-06 is under clinical development by Curacle and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 82% phase transition success rate ...